Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-313 in Malignant Ascites
NCT04051112Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilunermin alfa in malignant ascites, sponsored by Clover Biopharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
rilunermin alfa
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT04051112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051112.